All Outputs (2)

CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model (2020)
Journal Article
Ketley, A., Wojciechowska, M., Ghidelli-Disse, S., Bamborough, P., Ghosh, T. K., Morato, M. L., …Brook, J. D. (2020). CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. Science Translational Medicine, 12(541), Article eaaz2415. https://doi.org/10.1126/scitranslmed.aaz2415

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Myotonic dystrophy type 1 (DM1) is an RNA-based disease with no current treatment.... Read More about CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.

Developing Mn-doped lead sulfide quantum dots for MRI labels (2016)
Journal Article
Turyanska, L., Moro, F., Patanè, A., Barr, J., Köckenberger, W., Taylor, A., …Thomas, N. R. (2016). Developing Mn-doped lead sulfide quantum dots for MRI labels. Journal of Materials Chemistry B, 4(42), 6797-6802. https://doi.org/10.1039/c6tb02574a

Magnetic interactions of Mn2+ions in lead sulfide (PbS) nanocrystals with protons in water are probed by NMR and MRI. A thin layer of capping molecules enables free solvent diffusion to the nanocrystal surface resulting in a decrease of proton relaxa... Read More about Developing Mn-doped lead sulfide quantum dots for MRI labels.